Oslo, Norway, June 13, 2022 - Nykode Therapeutics ASA (Euronext Growth (Oslo):
NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and
development of vaccines and novel immunotherapies, announced today the
appointment of Klaus Edvardsen, M.D., Ph.D., as Chief Development Officer. The
appointment will take effect on July 1, 2022.

Chief Executive Officer of Nykode Therapeutics, Michael Engsig, said: "I am very
pleased to welcome Klaus to Nykode Therapeutics' executive management team.
Klaus brings tremendous international leadership experience in directing
successful drug development programs at renowned biopharmaceutical companies. As
Nykode's candidates continue to advance through the clinical, we are eager for
Klaus' significant contributions to our drug development strategies." 

"I am very excited to be joining Nykode Therapeutics," said Klaus Edvardsen,
M.D., Ph.D. "Nykode has developed a unique platform technology and has entered
into some impressive collaborations and partnerships with world-class
biopharmaceutical companies. With its strong development pipeline, Nykode has
built a great momentum on its quest to develop game changing medicines across an
expanding range of therapeutic areas and I look forward to joining the team."

Klaus Edvardsen joins Nykode from CureVac where he held a similar role as Chief
Development Officer. Other previous roles include Senior Vice President and Head
of Global Oncology Development of Merck KGaA, where he led early- and late-stage
global oncology development. Prior to these roles, he served as Senior Vice
President and Head of Global Medicines Development Oncology at AstraZeneca,
where he was responsible for the overall development strategy for oncology and
hematology programs. Klaus Edvardsen also held leadership roles at both
GlaxoSmithKline and Genmab in medicines development within various therapeutic
areas. Klaus Edvardsen holds a M.D. degree as well as a Ph.D. in cancer biology
from University of Copenhagen.


About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to
the discovery and development of vaccines and novel immunotherapies for the
treatment of cancer and infectious diseases. Nykode's modular vaccine technology
specifically targets antigens to Antigen Presenting Cells, which are essential
for inducing rapid, strong and long-lasting antigen specific immune responses
and eliciting efficacious clinical responses. 

Nykode's lead product candidates are VB10.16, a therapeutic vaccine for the
treatment of human papilloma virus (HPV)-16 induced malignancies which
demonstrated positive interim efficacy and safety results from its Phase II
trial for the treatment of cervical cancer